MRK · News · 20260917N

Product / Drug Pipeline Progress

Merck & Co., Inc. · 2026-09-17 · Importance 23 · Surprise 24

Merck is broadening its commercial portfolio beyond Keytruda with newer products Winrevair, Welireg, and Capvaxive. Third-party reporting characterizes these offerings as performing successfully and helping reduce the company’s dependence on its flagship oncology franchise. The products span pulmonary hypertension, oncology, and pneumococcal vaccination markets, strengthening Merck’s positioning across multiple healthcare end markets.

Key facts

• These new offerings are helping to reduce Merck's dependence on its blockbuster cancer drug Keytruda. source
• Auxier Asset Management highlighted Merck & Co. (MRK) in its Q2 2026 investor letter, noting the company's successful execution with new products like Winrevair, Welireg, and Capvaxive. source